Breaking news on ropeginterferon for PV patients. In December of 2018, we shared the news that CHMP (The Committee for Medicinal Products for Human Use; European Medicines Agency’s committee responsible for elaborating the agency’s opinions on all issues regarding medicinal products for human use) gave a positive opinion on ropeginterferon and recommended granting market authorization in the EU. According to a press release published by AOP Orphan, ropeginterferon, known as Besremi in the European Market, has gained marketing approval from the European Medicines Agency. It also stated that the drug may be available to PV patients within the first half of 2019.
Click here to read the entire press release.